Loading
A phase 2 trial of Aglatimagene besadenovec in non-small-cell lung cancer and small-cell lung cancer, run by Candel Therapeutics, Inc., active and no longer recruiting.
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC is a phase 2 interventional study registered as NCT04495153 by Candel Therapeutics, Inc., with 90 participants enrolled, started 2020-10-13 and due to reach its primary completion in 2024-12-31. Interventions recorded: Aglatimagene besadenovec. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Aglatimagene besadenovec, Candel Therapeutics, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/